TP53 and acute myeloid leukemia: The anti-CCRL2 ADC showed overall similar or lower cytotoxicity compared to Gemtuzumab and PBD-conjugated ADCs targeting CD33 and CD123 in the AML cell lines derived from de novo/ TP53-wild type AML (Fig. 2A, C).